Loading
Labcorp's tissue gene test for solid tumours, covering 523 genes with a 7 to 10 day turnaround and an option to add PD-L1 testing on the same sample.
OmniSeq INSIGHT is Labcorp's tissue comprehensive genomic profiling test for solid tumours, with a stated turnaround of 7 to 10 days. It reads the full coding sequence of 523 cancer-related genes for single-nucleotide variants, insertions and deletions, amplifications and translocations, and RNA from 55 genes for fusions and splice variants, and it reports microsatellite instability and tumour mutational burden; Labcorp's assay specifications list homologous recombination deficiency reporting as an option. It can be combined with PD-L1 testing on the same tissue. The clinical test is a laboratory-developed test; Labcorp also offers the assay to drug developers for research and investigational use, and a plasma version, OmniSeq INSIGHT ctDNA, for research use only.
Sequencing of the full coding sequence of 523 cancer-related genes in tumour DNA, and of 55 genes in tumour RNA for fusions and splice variants, from formalin-fixed tissue.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"OmniSeq INSIGHT" OR ABSTRACT:"OmniSeq INSIGHT" OR TITLE:"Labcorp OmniSeq INSIGHT" OR ABSTRACT:"Labcorp OmniSeq INSIGHT" OR TITLE:"OmniSeq INSIGHT Genomic Profiling Assay" OR ABSTRACT:"OmniSeq INSIGHT Genomic Profiling Assay") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OmniSeq INSIGHT, not a curated reading list.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Homologous recombination deficiency (HRD), Tumour mutational burden (TMB) and the tag test.
Shares Reference laboratories and companion-diagnostic testing, Homologous recombination deficiency (HRD), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares MSI-high (microsatellite instability by PCR or sequencing), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Metastatic cancer (cancer that has spread) and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/